Sanofi Price to Book Ratio 2012-2025 | SNY
Historical price to book ratio values for Sanofi (SNY) over the last 10 years. The current price to book ratio for Sanofi as of March 13, 2026 is 1.38.
| Sanofi Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-03-13 | 43.60 | 0.00 | |
| 2025-12-31 | 48.46 | 0.00 | |
| 2025-09-30 | 47.20 | 0.00 | |
| 2025-06-30 | 48.31 | $32.49 | 1.49 |
| 2025-03-31 | 53.11 | 0.00 | |
| 2024-12-31 | 46.18 | $33.35 | 1.38 |
| 2024-09-30 | 55.18 | 0.00 | |
| 2024-06-30 | 46.46 | $31.04 | 1.50 |
| 2024-03-31 | 44.65 | 0.00 | |
| 2023-12-31 | 45.68 | $31.81 | 1.44 |
| 2023-09-30 | 49.28 | 0.00 | |
| 2023-06-30 | 49.51 | $31.50 | 1.57 |
| 2023-03-31 | 48.11 | 0.00 | |
| 2022-12-31 | 42.81 | $31.40 | 1.36 |
| 2022-09-30 | 33.61 | 0.00 | |
| 2022-06-30 | 44.23 | 0.00 | |
| 2022-03-31 | 43.67 | 0.00 | |
| 2021-09-30 | 41.00 | 0.00 | |
| 2021-03-31 | 40.54 | 0.00 | |
| 2020-09-30 | 41.12 | 0.00 | |
| 2020-03-31 | 34.55 | 0.00 | |
| 2019-09-30 | 36.61 | 0.00 | |
| 2019-03-31 | 33.59 | 0.00 | |
| 2018-03-31 | 28.94 | 0.00 | |
| 2017-12-31 | 31.05 | $26.26 | 1.18 |
| 2017-09-30 | 35.95 | 0.00 | |
| 2017-06-30 | 34.59 | $25.22 | 1.37 |
| 2017-03-31 | 31.64 | 0.00 | |
| 2016-12-31 | 28.27 | $24.72 | 1.14 |
| 2016-09-30 | 26.70 | 0.00 | |
| 2016-06-30 | 29.26 | $23.85 | 1.23 |
| 2016-03-31 | 26.94 | 0.00 | |
| 2015-09-30 | 31.85 | 0.00 | |
| 2015-06-30 | 33.23 | $23.95 | 1.39 |
| 2014-06-30 | 34.52 | 0.00 | |
| 2013-06-30 | 32.27 | 0.00 | |
| 2012-06-30 | 22.88 | 0.00 | |
| 2012-03-31 | 22.37 | 0.00 | |
| 2011-12-31 | 21.10 | 0.00 | |
| 2011-09-30 | 18.94 | 0.00 | |
| 2011-06-30 | 23.19 | 0.00 | |
| 2011-03-31 | 19.40 | 0.00 | |
| 2010-12-31 | 17.75 | 0.00 | |
| 2010-09-30 | 18.31 | 0.00 | |
| 2010-06-30 | 16.56 | 0.00 | |
| 2010-03-31 | 19.51 | 0.00 | |
| 2009-12-31 | 20.51 | 0.00 | |
| 2009-09-30 | 19.30 | 0.00 | |
| 2009-06-30 | 15.40 | 0.00 | |
| 2009-03-31 | 13.84 | 0.00 | |
| 2008-12-31 | 15.93 | 0.00 | |
| 2008-09-30 | 16.29 | 0.00 | |
| 2008-06-30 | 16.47 | 0.00 | |
| 2008-03-31 | 17.87 | 0.00 | |
| 2007-12-31 | 21.68 | 0.00 | |
| 2007-09-30 | 20.20 | 0.00 | |
| 2007-06-30 | 19.17 | 0.00 | |
| 2007-03-31 | 20.22 | 0.00 | |
| 2006-12-31 | 21.46 | 0.00 | |
| 2006-09-30 | 20.67 | 0.00 | |
| 2006-06-30 | 22.63 | 0.00 | |
| 2006-03-31 | 21.63 | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $112.219B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |